T2D as an Important Starting Point of Heart Failure – Early Intervention for Heart Failure Patients

Abstract

SGLT2i has shown benefit in T2D patients. Several studies have also shown its benefit for cardiovascular complication, such as heart failure. Heart failure is an often missed complications in T2D patients. Dapagliflozin has shown benefit to reduce the hospitalization rate of heart failure in the T2D population, with several guidelines backing up the usage of SGLT2i in patients with high risk and heart failure complications.